High mobility group box 1 and tumor growth factor<b>β</b>: useful biomarkers in pediatric patients receiving peritoneal dialysis

Chimenz, Roberto; Lacquaniti, Antonio; Colavita, L; Chirico, Valeria; Fede, C; Buemi, Michele; Fede, C

doi:10.1080/0886022x.2016.1216711

Cited by 10 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, some evidence indicates that although PD has a lower mortality rate than HD in the first 1-2 years, it has a higher mortality rate after that. On the other hand, other registry data contradict this conclusion [67,68].…”

Section: Dialysis Technological Improvement Goalsmentioning

confidence: 99%

Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cardiorenal syndrome (CRS) is defined as a disorder resulting from the abnormal interaction between the heart and kidney, in which acute or chronic dysfunction of one organ may lead to acute and/or chronic dysfunction of the other. The functional interplay between the heart and kidney is characterized by a complex bidirectional symbiotic interaction, regulated by a wide array of both genetic and environmental mechanisms. There are at least five known subtypes of CRS, based on the severity of clinical features and the degree of heart/renal failure. The fourth subtype (cardiorenal syndrome type 4 (CRS4)) is characterized by a primary chronic kidney disease (CKD), which in turn leads to a decreased cardiac function. Impairment of renal function is among the most important pathophysiological factors contributing to heart failure (HF) in the pediatric age group, and cardiovascular complications could be one of the most important causes of mortality in pediatric patients with advanced CKD. In this context, a loss of glomerular filtration rate directly correlates with both the progression of cardiovascular complications in CRS and the risk of HF. This review describes the interaction pathways between the heart and kidney and the recently identified pathophysiological mechanisms underlying pediatric CRS, with a special focus on CRS4, which encompasses both primary CKD and cardiovascular disease (CVD).

show abstract

Section: Dialysis Technological Improvement Goalsmentioning

confidence: 99%

Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…In children who require peritoneal dialysis, peritonitis is the most important complication associated with peritoneal dysfunction and treatment failure, 204 and measuring new biomarkers of proinflammatory or anti‐inflammatory factors and fibrosis in dialysate can be used as a noninvasive method for the indirect evaluation of the peritoneum. The serum and peritoneal fluid HMGB1 levels peak in the early stage of acute peritonitis and gradually decrease with treatment, suggesting that HMGB1 may be used as a biomarker to evaluate peritoneal status and therapy response 205 . Finally, alcohol abuse in adolescence leads to increased expression of HMGB1 and TLRs/RAGE in the prefrontal cortex in adulthood, and this activated neuroinflammatory response plays an important role in the mechanism of alcohol addiction 206,207 …”

Section: Role Of Hmgb1 In Pediatric Diseasesmentioning

confidence: 99%

The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic

Peng

et al. 2020

Immunity Inflam & Disease

View full text Add to dashboard Cite

Introduction The ubiquitously expressed nonhistone nuclear protein high‐mobility group box protein 1 (HMGB1) has different functions related to posttranslational modifications and cellular localization. In the nucleus, HMGB1 modulates gene transcription, replication and DNA repair as well as determines chromosomal architecture. When the post‐transcriptional modified HMGB1 is released into the extracellular space, it triggers several physiological and pathological responses and initiates innate immunity through interacting with its reciprocal receptors (i.e., TLR4/2 and RAGE). The effect of HMGB1‐mediated inflammatory activation on different systems has received increasing attention. HMGB1 is now considered to be an alarmin and participates in multiple inflammation‐related diseases. In addition, HMGB1 also affects the occurrence and progression of tumors. However, most studies involving HMGB1 have been focused on adults or mature animals. Due to differences in disease characteristics between children and adults, it is necessary to clarify the role of HMGB1 in pediatric diseases. Methods and Results Through systematic database retrieval, this review aimed to first elaborate the characteristics of HMGB1 under physiological and pathological conditions and then discuss the clinical significance of HMGB1 in the pediatric diseases according to different systems. Conclusions HMGB1 plays an important role in a variety of pediatric diseases and may be used as a diagnostic biomarker and therapeutic target for new strategies for the prevention and treatment of pediatric diseases.

show abstract

“…This molecule was also evaluated in blood and peritoneal dialysis (PD) effluence in adult and pediatric PD patients with acute clinical peritonitis. A significant elevation of HMGB1 distinguished these patients with a gradual decline in its values during effective antibiotic treatments, suggesting a diagnosis and prognostic properties [ 18 , 19 ].…”

Section: Introductionmentioning

confidence: 99%

Free Light Chains, High Mobility Group Box 1, and Mortality in Hemodialysis Patients

Lacquaniti

Campo

Falliti

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Background: Uremic toxins are associated with immune dysfunction and inflammation. The inadequate removal by hemodialysis (HD) of serum free light chains (FLCs) determines their accumulation. This study evaluated FLCs in HD patients, analyzing their relations with other biomarkers, such as serum high mobility group box 1 (HMGB1). Methods: FLC and HMGB1 were evaluated in a cohort of 119 HD patients. κFLC and λFLC were summated to give a combined (c) FLC concentration. Patients were followed prospectively until the end of the observation period of four years, or until the endpoint: the patient’s death. Results: cFLC values in HD patients were 244.4 (197.9–273.5) mg/L. We detected a significant reduction in CD8+ cells and a decreased CD4+/CD8+ ratio. HMGB1 levels were 94.5 (55–302) pg/mL. After multivariate analysis, cFLCs correlated with β2-microglobulin and the CD4+/CD8+ ratio. Subjects with cFLC values above 263 mg/L and with sHMGB1 values < 80 pg/mL experienced a significantly faster evolution to the endpoint (mean follow-up time to progression of 27.5 and 28.5 months, respectively; p < 0.001). After an adjusted multivariate Cox analysis, cFLCs were associated with 11% increased risk of death, whereas low sHMGB1 increased this risk by 5%. Conclusions: cFLCs and HMGB1 reflect the inflammation and immune dysfunction in HD patients representing two strong and independent risk markers of mortality.

show abstract

High mobility group box 1 and tumor growth factorβ: useful biomarkers in pediatric patients receiving peritoneal dialysis

Abstract: HMGB1 represents a useful biomarker for peritoneum evaluation in PD patients. A prognostic role of this alarmin, as a marker of response to therapy, could be hypothesized. TGF-β could predict the peritoneal transport status and dialysis technique adequacy.

Cited by 10 publications

References 24 publications

Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes

Update on the Classification and Pathophysiological Mechanisms of Pediatric Cardiorenal Syndromes

The performance of the alarmin HMGB1 in pediatric diseases: From lab to clinic

Free Light Chains, High Mobility Group Box 1, and Mortality in Hemodialysis Patients

Contact Info

Product

Resources

About